GEA
IONS icon

Glen Eagle Advisors’s Ionis Pharmaceuticals IONS Stock Holding History

Glen Eagle Advisors’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-65
Closed -$3.93K – 897
2019
Q4 		$3.93K Buy
+65
New +$3.87K ﹤0.01% 733

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Glen Eagle Advisors's IONS Position: Q1 2020 in Review

Glen Eagle Advisors sold out of Ionis Pharmaceuticals (IONS) in Q1 2020, closing a stake of 65 shares — an estimated $3.93K sold.

Glen Eagle Advisors first reported a position in IONS in Q4 2019 and held it in 1 quarter. The position peaked at $3.93K in Q4 2019. 362 funds tracked by Wall St. Rank hold IONS as of Q1 2020.

  • Glen Eagle Advisors reported no remaining Ionis Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Glen Eagle Advisors sold 65 Ionis Pharmaceuticals shares in Q1 2020, an estimated $3.93K.
  • Glen Eagle Advisors first reported a position in Ionis Pharmaceuticals in Q4 2019 and held it in 1 quarter.
  • Glen Eagle Advisors's Ionis Pharmaceuticals position peaked at $3.93K in Q4 2019.
  • 362 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2020.

Based on Glen Eagle Advisors's 13F filing for Q1 2020, filed 13 Aug 2024.